Comment from Vanda Pharmaceuticals Inc.

Summary: Vanda Pharmaceuticals Inc. argues that the Draft Guidance is insufficient because it fails to fully implement the agency's goal of replacing animal testing with human-centric methodologies. The company recommends several revisions, including removing requirements to benchmark new approach methodologies (NAMs) against animal studies and rescinding outdated international guidelines that mandate lengthy animal testing.